p73, a ®rst p53 relative, was recently identi®ed and shown to be monoallelically expressed in a number of dierent human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and tumor tissues using quantitative RT ± PCR analysis, we found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identi®ed T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-speci®c mutations in any coding exons of the p73 gene. These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.
Introduction
Bladder cancer is the most common type of urinary cancer, and is the ®fth most common cancer in men and seventh in women in USA (Parker et al., 1996) . Malignant transformation of bladder epithelium has been associated with a number of molecular alterations in the c-Ha-ras proto-oncogene (Reddy et al., 1982; Fujita et al., 1985) and tumor suppressor genes (Knowles et al., 1994; Cordon-Cardo et al., 1997) . One tumor suppressor, p53, was reported to be abnormal in approximately 50% of bladder cancers (Goto et al., 1997) . In addition, the nuclear overexpression of p53 has been correlated with p53 mutations, and p53 accumulation was signi®cantly associated with an increased risk of tumor recurrence and poor prognosis (Cordon-Cardo et al., 1994; Sarkis et al., 1993) .
Recently, p73 was identi®ed as the ®rst homolog of p53. It shares signi®cant amino-acid sequence identity to p53 in all three domains (Kaghad et al., 1997) , and it can activate the cell cycle inhibitor p21/waf1/cip1 and induce apoptosis (Jost et al., 1997) . However, unlike p53, it is not activated following exposure to DNA-damaging agents such as Actinomycin D and UV irradiation. In addition, p73 was localized to 1p36.33, a region that shows frequent deletions in neuroblastoma and other neuroectodermal tumors such as melanoma and multiple endocrine neoplasm (Takeda et al., 1994; Versteeg et al., 1995) . Finally, p73 was monoallelically expressed in several cancer cell lines and normal human peripheral blood (Kaghad et al., 1997) . All this data suggests that p73 is a candidate imprinted tumor suppressor gene.
In this report, we investigated the potential involvement of p73 in the development of bladder cancer by quantitatively analysing expression levels, allelic expression patterns, and by screening for somatic mutations in the p73 gene in 23 pairs of bladder cancers with matched normal tissues. Our results indicate that p73 is not imprinted in bladder tissues nor is it a tumor suppressor gene for bladder cancer, but it could be involved in the pathogenesis of bladder cancer by overexpression.
Results and Discussion

Expression of p73 alleles
We ®rst studied allele-speci®c expression of the p73 gene in seven bladder cancer cell lines and 23 pairs of invasive bladder cancers with matched normal tissues. All the bladder tumors were transitional cell carcinoma, of grades 2 ± 4 and were obtained from patients who underwent radical cystectomies. We identi®ed 11 informative individuals by genomic PCR ampli®cation using primers located in introns 1 and 2, followed by StyI digestion. Several representative samples are shown in Figure 1a . Allele-speci®c expression of p73 in paired tumor and normal tissues from these informative individuals were studied by RT ± PCR with cDNA primers¯anking the C/T polymorphism and the StyI restriction fragment length polymorphism (RFLP) (Figure 1b) . We identi®ed biallelic expression of p73 in both normal and tumor bladder tissues in all the samples examined ( Figure 1b) . One informative cell line, EJ-1 also expressed both alleles of p73 (data not shown). Using a newly identi®ed polymorphism in exon 5, which is a BanI RFLP, we found seven informative cases (Figure 1c) . In these samples, we also observed biallelic expression in all seven cancers and matched normal tissues (Figure 1d ) as well as in two cell lines, SNK57 and T24 (data not shown).
p73 was originally reported as a monoallelically expressed gene by Kaghad et al. (1997) based on the monoallelic expression patterns found in all human cell lines and ®ve normal human peripheral blood samples examined. Moreover, they also analysed one informative case and found that p73 was predominantly expressed from the maternal allele, suggesting that p73 could be a paternally imprinted tumor suppressor gene. We recently analysed allelic expression of p73 in two types of human cancers and reported that monoallelic expression of p73 was evident in normal lung (5/5) and renal tissues (10/12) (Mai et al., 1998a,b) but the gene was biallelically expressed in matched lung cancer samples (5/5) and renal cancer samples (10/12). These results supported the hypothesis that p73 is an imprinted gene. Loss of imprinting (LOI) of p73 is associated with the development of lung and renal cancers. However, when we analysed bladder cancers, we found that p73 expression was biallelic in all cancers and matched normal tissues which were informative for either StyI or BanI RFLPs. This is also true for prostate cancer and matched normal tissues found in our recent study (Yokomizo et al., manuscript in preparation) . Thus, data reported here indicates that both alleles of the p73 gene are retained and p73 is not monoallelically expressed in bladder tissues. It seems that monoallelic expression of p73 is not strictly maintained in all human tissues and it could be tissue origin dependant or physiological condition dependant. Investigating the tissue speci®c imprinting and analysing the allelic expression of p73 homolog in mouse will help to explain these evidences.
Overexpression of p73 in bladder cancer
In our previous report (Mai et al., 1998a) , we demonstrated that the p73 gene was overexpressed in lung cancer relative to matched normal tissues. To see if this was also the case for bladder cancers, we compared expression levels of p73 between the bladder cancers and matched normal tissues using quantitative RT ± PCR. PCR was performed for 30 cycles with increasing copy numbers of competitor. Figure 2a shows that the copy numbers of cDNA from the bladder cancers were estimated around 100 copies per 50 ng total tumor RNA, and the increased numbers of competitor inhibited the amplicon synthesis from the wild type cDNA. Under these conditions, quantitative PCR was performed and dramatic p73 overexpression in bladder cancer was observed in 22 out of 23 cases.
Results from seven pairs of bladder cancer and matched bladder tissues were shown in Figure 2b . The p73 is average about sixfold overexpressed in bladder cancer than in matched normal tissues ( Figure  2c ). In one case, the expression of p73 in cancer is about 20-fold increased than in its matched normal tissue (data not shown). Thus, p73 overexpression could play an important role in bladder carcinogenesis.
Comparison of p73a and p73b expression p73 has an alternative splicing product, p73b, which is identical to the normal splicing product, p73a, but lacks exon 13 (Kaghad et al., 1997) . We designed primers in exon 12 and exon 14 to distinguish between these two transcripts by semi-quantitative RT ± PCR analysis to see if the overexpression of p73 in bladder cancer was due to the unbalanced expression of either a or b transcripts. As shown in Figure 3 , we found that p73a was the dominant transcript in both bladder cancer and normal tissues. The expression ratio of the p73a and p73b is about 1.6:1 in both cancer and normal bladder tissues. Thus, the overexpression of p73 in bladder tumor is due to balanced overexpression of both transcripts of the p73 gene.
Mutation analysis of p73 in bladder cancers
Since p53 abnormality has been found in 50% of bladder cancers and p73 is a homolog of p53, we examined the mutational status of p73 in bladder cancers to see the possible involvement of this gene.
We identi®ed the genomic structure of this gene, and a total of 13 pairs of primers were synthesized to cover all the coding region and the intron/exon junction site sequences of p73 (Mai et al., 1998c) . Twenty-three bladder cancer samples and seven bladder cancer cell lines were then analysed for p73 mutations. After denaturing and reannealing, the PCR products from each exon were analysed on the DHPLC system based on the separation of heteroduplexes from homoduplexes (Yokomizo et al., 1998a,b) . The PCR products showing heteroduplexes were directly sequenced to identify sequence variations. Denaturing HPLC is a very robust technique to detect sequence variation with very high eciency (95%) and can detect one base pair mismatch in a 1 Kb amplicon (Liu et al., 1998) . However, no single mutations were detected in all the bladder cancers. Instead, several polymorphisms in the dierent exons and introns of p73 were identi®ed occurring at similar frequencies as we found in other types of tumors before (Mai et al., 1998a,c) .
In summary, we have characterized p73 and found that this gene is not mutated in primary bladder cancers and cell lines. Thus p73 is not a tumor suppressor involved in the development of bladder cancer. Similar studies of the p73 in a number of dierent tumor types, including oligodendrogliomas (Mai et al., 1998c) , lung cancers (Mai et al., 1998a) , and renal cell carcinomas (Mai et al., 1998b) has failed to identify mutations in this gene in any of the studied tumors. However, we did ®nd that this gene was overexpressed from both p73a and p73b transcripts in bladder cancer, indicating that increases in expression are not due to unbalanced processing of p73 transcripts. Furthermore, p73 was biallelically expressed in both bladder cancer and normal tissues, implying that the p73 gene is not imprinted in bladder tissue and it could be tissue-speci®c imprinted gene.
Materials and methods
Tissue specimens, cell lines and isolation of DNA Twenty-three primary bladder carcinomas with matched normal tissues were obtained from patients diagnosed with invasive bladder cancer who had radical cystectomy at the Mayo Clinic (Rochester, MN, USA). All the patients were newly diagnosed and none had received systemic therapy. All the bladder cancers were histopathologically diagnosed as transitional cell carcinomas (grades 2 ± 4) postoperatively. The experienced pathologists determined tumor cell population as almost 90% in every bladder tissues that we used. Every matched normal tissue specimen examined had no contaminating tumor cells as determined by hematoxylin and eosine staining. The cell lines KK47, KU-1, KU-7, NK-B1, SNK-57, EJ-1 and T24 were kindly provided from the Department of Urology (Kyushu University, Japan). Their isolation, characterization and culture conditions were as previously described (Tazaki and Tachibana 1988; Miyazaki et al., 1993; Naito et al., 1996) . DNAs from each sample were isolated and puri®ed as previously reported (James et al., 1988) .
DHPLC analysis
Genomic PCR ampli®cation of all coding exons of the p73 gene and their splice site junction sequences were performed using intronic primers determined from our previous analysis of the genomic organization of this gene a b Figure 3 (a) Comparison of the expression level of the p73a and p73b. RT ± PCR was performed with the primers that covered p73 exon 13. (b) The amounts of p73a and b transcripts from the ten matched samples were estimated by measuring the band intensities. p73a was dominantly expressed (1.6-fold) both in normal and tumor tissues, however, no signi®cant dierences were observed between normal and tumor tissues p73 overexpression in bladder cancer A Yokomizo et al (Mai et al., 1998c) . The genomic amplicons were con®rmed by 1.5% agarose gel electrophoresis and were subsequently examined for heteroduplex content by subjecting 4 ± 7 ml of each sample, containing approximately 50 ± 100 ng of amplicons, to high performance liquid chromatography (DHPLC) under conditions of partial denaturation (Oefner and Underhillo, 1995; Liu et al., 1998) . The DHPLC system can separate DNA heteroduplexes from homoduplexes, so that we can identify PCR products that had sequence variations (Yokomizo et al., 1998a,b) . The samples which showed heteroduplex pro®les were directly sequenced as described below.
DNA sequencing
PCR products for sequencing were treated with exonuclease and shrimp alkaline phosphatase based on the protocol provided by United States Biochemical. They were mixed with 3.2 pmol of forward or reverse primer speci®c for each amplicon and then sent for sequencing to the Molecular Core Facilities in Mayo Clinic. Sequencing reactions were performed in a DNA Thermal Cycler 9600 (Perkin-Elmer Cetus) with¯uorescent ddNTP's, and sequencing products were analysed on an ABI 377 automated sequencer.
Competitive RT ± PCR
Reverse transcription was performed with 2 mg of total RNA according to the manufacturer's protocol (Gibco-BRL). PCR was performed using forward primer, p73s685: 5'-AACGCTGCCCCAACCACGAG, and reverse primer, p73as896: 5'-GCCGGTTCATGCCCCCTACA. For competitive PCR, we made a control vector (pGEM/p73) which contains a 200 bp p73 insert that is 31 bp shorter than wild type as a competitive PCR template. This 200 bp insert was created by PCR ampli®cation using the same forward primer p73s685 as above and a 38 mer reverse primer 5'-GCCGGTTCATGCCCCCTACA ± TGGTGGTGAATTC-CGTCC. The reverse primer was designed based on the p73 cDNA sequence from nucleotide 847 ± 915 with a 31 base deletion between nucleotides 865 ± 895. The amplicon was then sequenced and subcloned into the pGEM T-vector (Promega, Madison, WI, USA). The copy number of p73 competicon were calculated by its UV absorbance. Quanti®cation of p73 expression was determined by competitive PCR. First, PCR was performed with the titration of increasing numbers (0 ± 2000) of p73 competicon (Figure 2a ) with most highly expressed bladder cancer tissue cDNA. PCR was completed using AmpliTaq Gold and the 9600 PCR Thermal Cycler (Perkin Elmer) under the following conditions: 958C 9 min for activation of AmpliTaq, followed by 958C for 20 s, 588C for 20 s, and 728C for 30 s for a total of 30 cycles. This titration indicates that there are 100 copies of endogenous p73 transcripts in 50 ng total tumor RNA. Then, comparison of the expression levels between normal bladder (N) and tumor (T) were performed in all the samples under the same PCR condition (Figure 2b ). The amounts of PCR products from matched samples were estimated from the measurement of band intensities by Gel Doc (Bio-Rad) and its associated software. Statistical analysis were carried out by Student's t-test.
Allelic expression of p73
To identify exon 2 polymorphisms, intronic primers for exon 2 (p73 E2S: 5'-CAGGAGGACAGAGCACGAG and p73 E2AS: 5'-CGAAGGTGGCTGAGGCTAG) were used to perform the PCR from genomic DNA. The PCR conditions were, 958C for 20 s, 608C for 15 s and 728C for 30 s for 35 cycles. This yields a speci®c 229 bp fragment. Eight ml of the PCR product was then digested with StyI overnight. Samples that were found to be heterozygous (11 cases out of 23 samples) were used for RT ± PCR analysis to examine allelic expression. First strand cDNAs were reverse transcribed with 250 ng of random primers following the manufacturer's protocol (Gibco-BRL). Primer pairs (5'-CGGGACGGACGCC-GATG and 5'-CCCCGGCTTGACTGGGGAAG) were used for ampli®cation under the following conditions: 958C for 20 s, 648C for 20 s and 728C for 30 s for 25 cycles. One ml of PCR products were then ampli®ed by nested PCR with the internal primers (5'-GGGCTGCGACGGCTGCAGAGC and 5'-GAGAGCTC-CAGAGGTGCTC) under the same condition except the annealing temperature at 588C. Seven ml of the PCR product was then digested with StyI overnight. The digested products were then analysed on an 8% polyacrylamide gel. For the exon 5 polymorphism, intronic primers for exon 5 (p73 E5S 5'-CTGGACAGGGGTG-CAGTTG and p73 E5AS 5'-TGCTGTCCGGGATGCTG) were used to identify informative cases. The polymorphic individuals (seven cases out of 23 samples) were then examined for their allelic expression by RT ± PCR followed by BanI digestion. The expressed alleles were ampli®ed with primer pairs (5'-TCAGCCACCTGGACGTACTC and 5'-GTCACGTGCTCCGCTTTCTT) under the following conditions: 948C for 20 s, 608C for 20 s and 728C for 30 s for 35 cycles.
Analysis of expression levels of the two p73 transcripts: p73a and p73b
To compare the expression levels of p73a, and its alternative splicing product p73b, in bladder cancer and normal tissues, we performed semiquantitative RT ± PCR. As p73b lacks exon 13 (Kaghad et al., 1997) , we designed primer pairs covering that exon. Primers 5'-CATGGTCTCGGGGTCCCACT and 5'-CTGCTTCAG-GTCCTGCAG were used to dierentiate between p73a (232 bp) and p73b (138 bp). PCR was performed for 20, 25, 30, 35 and 40 cycles, at 958C for 20 s, 648C for 15 s and 728C for 30 s. We found that PCR products were linearly ampli®ed between 25 and 35 cycles (data not shown). To obtain similar band intensities for comparison, PCR cycle numbers were changed between tumor and normal samples (30 cycles for tumor and 33 cycles for normal). Band intensities were quanti®ed by the gel Doc 1000 photodocumentation system (Bio-Rad) and its associated software (Molecular Analyst).
